Anaptysbio (ANAB) Cash from Financing Activities (2016 - 2026)

Anaptysbio has reported Cash from Financing Activities for 11 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 104.23% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$102.8 million (down 191.72% YoY), and the FY2025 full-year result was -$132.6 million, down 204.38% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $1.2 million, up from -$43.1 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $71.2 million in Q3 2024, with the low at -$50.5 million in Q2 2025.
• Historically, Cash from Financing Activities has averaged -$1.2 million across 5 years, with a median of -$3.1 million in 2023.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 15263.9% — and 2023, when it sank 3223.15%.
• Anaptysbio's Cash from Financing Activities stood at $1.9 million in 2022, then sank by 364.7% to -$5.2 million in 2023, then surged by 634.35% to $27.6 million in 2024, then sank by 256.47% to -$43.1 million in 2025, then surged by 102.8% to $1.2 million in 2026.
• The last three Cash from Financing Activities figures came in at $1.2 million (Q1 2026), -$43.1 million (Q4 2025), and -$10.4 million (Q3 2025), per Business Quant data.